Phase 2Recruiting
Safety and Efficacy of Atorvastatin v. Placebo on HCC Risk (TORCH)
Multi-center Double Blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Long-term Atorvastatin (20 mg/Day) v. Placebo on HCC Risk in Individuals With Advanced Liver Fibrosis
- Sponsor
- Raymond Chung (Academic or other)
- Enrolment
- 60 planned
- Conditions
- Liver Fibroses; Cirrhosis
- Interventions
- Atorvastatin 20mg; Placebo
- Ages
- adults, older adults
- Registry
- NCT05028829
From the registry
Prospective randomized, multi-center, double blind placebo-controlled trial to assess the chemopreventive impact of atorvastatin (20 mg oral) vs placebo in up to 60 adults with advanced fibrosis at high risk of developing HCC.
Primary outcomes
- Reduced magnitude of high-risk PLSec after treatment vs before treatment